These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20970022)

  • 41. When is Vitamin D contraindicated in dialysis patients?
    Brown HJ; Cunningham J
    Semin Dial; 2009; 22(3):237-40. PubMed ID: 19572997
    [No Abstract]   [Full Text] [Related]  

  • 42. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
    Negri AL
    J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nicotinamide and phosphate homeostasis in chronic kidney disease.
    Ginsberg C; Ix JH
    Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):285-91. PubMed ID: 27219041
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Calcium and phosphate imbalances in renal failure.
    Lancaster LE
    Crit Care Nurse; 1981 Feb; 1(2):27-32. PubMed ID: 6914238
    [No Abstract]   [Full Text] [Related]  

  • 45. [Chronic kidney disease-mineral and bone disorder (CKD-MBD)].
    Hamada Y; Fukagawa M
    Nihon Rinsho; 2006 Sep; 64(9):1703-6. PubMed ID: 16972683
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The contribution of dialysis and laboratoristic methods for the control of phosphates].
    Bolasco P
    G Ital Nefrol; 2014; 31(2):. PubMed ID: 24777923
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.
    McCarley PB; Arjomand M
    Nephrol Nurs J; 2008; 35(1):59-64. PubMed ID: 18372764
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Managing bone mineral disorders in CKD: an overview of current therapies.
    Delaney M
    J Ren Care; 2009 Mar; 35 Suppl 1():107-10. PubMed ID: 19222741
    [No Abstract]   [Full Text] [Related]  

  • 49. How to prevent renal osteodystrophy.
    Lindenau K; Kokot F; Vetter K; Hohmann WD; Werner G; Buder R; Grossmann I; Fröhling PT
    Contrib Nephrol; 1984; 37():66-9. PubMed ID: 6609047
    [No Abstract]   [Full Text] [Related]  

  • 50. Phosphate binders. Is selection determined by price?: Yes.
    de Francisco AL
    Nefrologia; 2012; 32(2):235-9. PubMed ID: 22466264
    [No Abstract]   [Full Text] [Related]  

  • 51. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia.
    Savica V; Calò LA; Monardo P; Santoro D; Mallamace A; Muraca U; Bellinghieri G
    J Ren Nutr; 2009 Jan; 19(1):69-72. PubMed ID: 19121775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phosphate binders in hyperphosphatemia of chronic renal failure.
    Wasan SM; Godley PJ
    DICP; 1991 Sep; 25(9):942-5. PubMed ID: 1949972
    [No Abstract]   [Full Text] [Related]  

  • 53. Improvement in Hyperphosphatemia Using Phosphate Education and Planning Talks.
    Brauer A; Waheed S; Singh T; Maursetter L
    J Ren Nutr; 2019 Mar; 29(2):156-162. PubMed ID: 30087012
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bone disease in renal failure. Introduction.
    Malluche HH
    Miner Electrolyte Metab; 1991; 17(4):209-10. PubMed ID: 1813782
    [No Abstract]   [Full Text] [Related]  

  • 55. Phosphate elimination in modalities of hemodialysis and peritoneal dialysis.
    Kuhlmann MK
    Blood Purif; 2010; 29(2):137-44. PubMed ID: 20093819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment options for hyperphosphatemia in feline CKD: what's out there?
    Kidder AC; Chew D
    J Feline Med Surg; 2009 Nov; 11(11):913-24. PubMed ID: 19857854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dietitian-led education program to improve phosphate control in a single-center hemodialysis population.
    Reddy V; Symes F; Sethi N; Scally AJ; Scott J; Mumtaz R; Stoves J
    J Ren Nutr; 2009 Jul; 19(4):314-20. PubMed ID: 19539185
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patient empowerment in the management of hyperphosphatemia.
    Kuhlmann MK; Hoechst S; Landthaler I
    Int J Artif Organs; 2007 Nov; 30(11):1008-13. PubMed ID: 18067103
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preventing bone disease requires diligent management in patients with renal failure.
    Kolb FO
    West J Med; 1994 May; 160(5):475-7. PubMed ID: 8048242
    [No Abstract]   [Full Text] [Related]  

  • 60. Update on the new Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for mineral and bone disorders (MBD)--a focus on medications.
    Raymond CB; Wazny LD; Sood AR
    CANNT J; 2010; 20(1):42-6; quiz 47-8. PubMed ID: 20426360
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.